LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 142

Search options

  1. Article ; Online: Tofacitinib's infectious profile: concerns for clinical practice.

    Favalli, Ennio Giulio

    The Lancet. Rheumatology

    2020  Volume 2, Issue 2, Page(s) e65–e67

    Language English
    Publishing date 2020-01-13
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(20)30001-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?

    Favalli, Ennio Giulio / Caporali, Roberto

    The Lancet. Rheumatology

    2020  Volume 2, Issue 8, Page(s) e448–e449

    Language English
    Publishing date 2020-06-16
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(20)30185-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Managing patients with rheumatic conditions during the covid-19 pandemic.

    Caporali, Roberto / Favalli, Ennio Giulio

    BMJ (Clinical research ed.)

    2020  Volume 369, Page(s) m1633

    Keywords covid19
    Language English
    Publishing date 2020-04-27
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 1362901-3
    ISSN 1756-1833 ; 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
    ISSN (online) 1756-1833
    ISSN 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
    DOI 10.1136/bmj.m1633
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis.

    Cavalli, Giulio / Favalli, Ennio Giulio

    Expert review of clinical immunology

    2019  Volume 15, Issue 12, Page(s) 1313–1322

    Abstract: ... ...

    Abstract Introduction
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/immunology ; Arthritis, Rheumatoid/pathology ; Biological Products/therapeutic use ; Humans ; Observational Studies as Topic ; Randomized Controlled Trials as Topic ; Remission Induction
    Chemical Substances Antirheumatic Agents ; Biological Products
    Language English
    Publishing date 2019-11-10
    Publishing country England
    Document type Journal Article ; Review ; Video-Audio Media
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2020.1686976
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis.

    Maioli, Gabriella / Caporali, Roberto / Favalli, Ennio Giulio

    Expert opinion on drug discovery

    2022  Volume 17, Issue 8, Page(s) 799–813

    Abstract: Introduction: Rheumatoid arthritis (RA) pathogenesis is driven by a complex network of proinflammatory cytokines, among which interleukin-6 (IL-6) plays a key role in inducing and perpetuating chronic inflammation. Targeting the IL-6 pathway has shown ... ...

    Abstract Introduction: Rheumatoid arthritis (RA) pathogenesis is driven by a complex network of proinflammatory cytokines, among which interleukin-6 (IL-6) plays a key role in inducing and perpetuating chronic inflammation. Targeting the IL-6 pathway has shown to be an invaluable treatment strategy, as demonstrated by the results accrued in the last decade with the first IL-6 inhibitor, tocilizumab. More recently, a second monoclonal antibody blocking IL-6, sarilumab, has enriched our armamentarium by proving outstanding efficacy in RA treatment.
    Areas covered: After exploring the IL-6 pathway under physiological conditions and in the RA pathogenesis, in this review we discuss the pharmacologic properties of sarilumab and the clinical trials that constitute the sarilumab development program and have enabled its licensed application.
    Expert opinion: Results from clinical trials confirmed the efficacy and safety of sarilumab for the treatment of RA, similar to its precursor tocilizumab. Blocking IL-6 pathway results in comprehensive control of the disease, from both physician's and patient's perspective, and of RA comorbidities and extra-articular manifestations, which are largely IL-6 driven. Finally, the proven efficacy of sarilumab as monotherapy arises the drug as a required therapeutic alternative considering the large proportion of patients intolerant or inadequate to receive conventional synthetic disease-modifying drugs (csDMARDs).
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/drug therapy ; Humans ; Interleukin-6/therapeutic use ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antirheumatic Agents ; Interleukin-6 ; sarilumab (NU90V55F8I)
    Language English
    Publishing date 2022-06-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2259618-5
    ISSN 1746-045X ; 1746-0441
    ISSN (online) 1746-045X
    ISSN 1746-0441
    DOI 10.1080/17460441.2022.2093852
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors.

    Cavalli, Giulio / Favalli, Ennio Giulio

    Annals of translational medicine

    2017  Volume 6, Issue Suppl 1, Page(s) S82

    Language English
    Publishing date 2017-11-21
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm.2018.10.72
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: GM-CSF in the treatment of COVID-19

    Favalli, Ennio Giulio / Caporali, Roberto

    The Lancet Rheumatology

    a new conductor in the pathogenesis of cytokine storm?

    2020  Volume 2, Issue 8, Page(s) e448–e449

    Keywords covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ISSN 2665-9913
    DOI 10.1016/s2665-9913(20)30185-5
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Book ; Online: Managing patients with rheumatic conditions during the covid-19 pandemic

    Caporali, Roberto / Favalli, Ennio Giulio

    2020  

    Keywords LETTERS ; covid19
    Language English
    Publishing date 2020-04-27 03:11:17.0
    Publisher BMJ Publishing Group Ltd
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top